Plaque psoriasis & psoriatic arthritis patient who are anti-TNFα inadequate responders or patient w/ concomitant moderate to severe plaque psoriasis 300 mg SC inj given in 2 doses w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Some patient ≥90 kg may derive additional benefit from 300 mg every 2 wk. For some patient, 150 mg may be acceptable.
Psoriatic arthritis, AS & nr-axSpA 150 mg SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Ped patient ≥6 yr w/ plaque psoriasis or JIA categories of ERA & JPsA SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Ped <50 kg 75 mg,
≥50 kg 150 mg. Some patient w/ plaque psoriasis may derive additional benefit from higher dose (300 mg).
Sign Out
 150 mg_mLe923a17a-bf76-4fc0-a4e4-af7200e734a3.GIF)
